Staar Surgical (Nasdaq:STAA) announced today that it partnered with Tennessee Titans quarterback Will Levis to promote the EVO ICL. EVO Implantable Collamer lenses (ICLs) work in harmony with the natural eye to provide clear vision without causing dry eye. The FDA-approved lenses correct myopia, which affects distance vision, and myopia with astigmatism, which causes blurred […]
Staar Surgical
Staar Surgical appoints two new executives
Staar Surgical (Nasdaq:STAA) announced today that it appointed a new chief operating officer and chief clinical, regulatory and medical affairs officer. The Lake Forest, California-based implantable eye lens maker named Warren Foust as its new COO. Magda Michna takes over as chief clinical, regulatory and medical affairs officer. Staar’s global head of regulatory affairs, Denise […]
Staar Surgical CEO change leaves analysts with questions
Analysts called a recent corner office switch at Staar Surgical (Nasdaq:STAA) a “curve ball,” leaving them with questions about the company. Last week, Staar announced the retirement of CEO Caren Mason, who held the role since 2015. The company named its current board chair Thomas Frinzi as her replacement. Lake Forest, California–based Staar is the […]
Staar Surgical CEO Caren Mason retires, replacement named
Staar Surgical (Nasdaq:STAA) announced today that President and CEO Caren Mason intends to retire at the end of the year. Mason plans to retire on Dec. 31, 2022 from Staar, a creator of implantable lenses for the eye and companion delivery systems. Staar Surgical’s board appointed ophthalmic industry executive Thomas G. Frinzi — a veteran […]
Staar Surgical dips on Street-beating Q3, tightened guidance
Staar Surgical (Nasdaq:STAA) shares took a hit after hours on third-quarter results that came in ahead of the consensus forecast. Shares of STAA dipped 4.4% at $67.50 apiece after the market closed today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day down 0.3%. The […]
Staar Surgical rises on Street-beating Q1, Evo lens shipments remain ‘robust’
Staar Surgical (Nasdaq:STAA) shares got a boost this morning on first-quarter results that topped the consensus forecast. STAA shares were up 11% at $70.91 per share as the market opened today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was down 0.4%. However, Staar shares were down […]
Staar Surgical implants first EVO Visian implantable Collamer lens
Staar Surgical today announced the first implants of the Evo Visian implantable Collamer lens in the U.S. Lake Forest, California-based Staar Surgical designed the Evo biocompatible implantable lens for the correction of myopia and myopia with astigmatism. The first implant was performed in a woman with myopia and astigmatism in her thirties who previously used […]
Staar Surgical wins FDA approval for Evo Visian implantable Collamer lens
Staar Surgical (Nasdaq:STAA) announced today that it received FDA approval for its Evo/Evo+ Visian implantable Collamer lens. Lake Forest, California-based Staar Surgical designed the Evo biocompatible implantable lens for the correction of myopia and myopia with astigmatism. More than 1 million Evo lenses have been implanted by doctors outside the U.S., according to a news […]
Staar Surgical grows sales 28% in Q4 results
Staar Surgical (NSDQ:STAA) posted fourth-quarter results this week that beat the earnings consensus on Wall Street and missed revenue estimates. The Lake Forest, California-based company reported profits of $4.9 million, or 10¢ per share, on sales of $59 million for the three months ended Dec. 31, 2020, for a bottom-line gain of 47.9% on sales growth […]
Staar Surgical beats the Street in Q3, reports order backlog of more than 20,000 lenses
Staar Surgical (NSDQ:STAA) posted third-quarter results after markets closed yesterday that beat the consensus forecast on Wall Street and raised its outlook for the rest of the year. The Lake Forest, California-based implantable lens maker reported profits of $6.0 million, or $0.12 per diluted share, on sales of $58.4 million for the three months ended […]